IRCT20220211053991N1 IRCT 2023-06-12 Iran University of Medical Sciences Comparison of the effects of Rivaroxaban and Apixaban with Heparin and Enoxaparin in patients undergoing gynecological oncological surgery. Comparison of the effect of oral anticoagulants (Rivaroxaban and Apixaban) and injectable drugs (Heparin and Enoxaparin) to prevent bleeding in patients undergoing oncological gynecological surgeries 2023-06-09 anticipated 80 Complete https://irct.ir/trial/65862 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Referral patients are randomly divided into two groups receiving oral and injectable anticoagulation drugs. Random number table is used for randomization. Odd numbers for the oral anticoagulation group and even numbers for the injectable drug group. 2 Women's cancers including: endometrium, ovary, cervix, vulva. Intervention 1: The first intervention group: the group receiving oral anticoagulant tablets apixaban and rivaroxaban with a dose of 2/5 mg twice a day after surgery, for 28 days, manufactured by Aburihan Pharmaceutical Company of Iran. Intervention 2: Intervention group: The group receiving anticoagulation injection drugs (heparin and enoxaparin), with a dose of 5,000 units once a day after surgery, for 28 days, manufactured by Aburihan Pharmaceutical Company of Iran. No - There is not a plan to make this available Justification or reason for not sharing IPD is Patient information is confidential according to the ethical work protocol